Daiichi Sankyo Company, Limited

Ube Industries, Inc.

Naoki Terasaka

Hideki Kobayashi

Toshio Kaneko

Masami Arai

Takahiro Yamaguchi

Masahiko Hagihara

Hideki Kubota

Tsuyoshi Nakamura

Noriaki Iwase

Hidenori Namiki

Nobuyuki Ohkawa

Hidetoshi Sunamoto

Kozo Oda

Koji Ito

Katsunori Takata

Daisuke Takano

Kenji Yoneda

Kazuhiko Tamaki

Ira Glenn Schulman

Osamu Kikuchi

Daisuke Nakai

Masakazu Nakadai

Akiko Shima

Patricia J Willy

Brandee Lynn Wagner

Shoko Honzumi

Toshio Onoda

Kazunari Tsuboike

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and Ris a hydrogen atom or a hydroxy group. 

5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein Ris H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Substituted pyridine compound

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group. 

Piperidinylpyrazolopyridine derivative

A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator.

LXR ligand testing method

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R: &#x2014;COR(wherein R: alkyl, optionally substituted alkoxy or optionally substituted amino); R: H, OH, alkoxy, optionally substituted amino, etc.; R: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; Rand R: H, optionally substituted alkyl, halogeno, etc.; Rand R: H, alkyl; R: &#x2014;XR[wherein R: &#x2014;COR(wherein R: OH, optionally substituted alkoxy, optionally substituted amino, etc.), &#x2014;SOR(wherein R: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X: single bond, optionally substituted alkylene, etc.]; X: &#x2014;NH&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, etc.; Y: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

Benzene compound having 2 or more substituents

Growing community of inventors

Saitama, Japan

Naoki Terasaka